[Hengrui Medicine: Net profit attributable to parent company in the first three quarters was approximately 6.923 billion yuan A year-on-year increase of 20.38%] On October 27, Hengrui Pharmaceuticals (01276) announced its results for the first three quarters of 2026, with revenue of approximately 24.409 billion yuan, a year-on-year increase of 5.26%; attributable to shareholders of listed companies Net profit was approximately 6.923 billion yuan, a year-on-year increase of 20.38%; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 6.243 billion yuan, a year-on-year increase of 11.70%; basic earnings per share was 1.05 yuan. The company continues to increase innovation and maintain high R&D investment. In the first three quarters of 2026, the company's cumulative R&D investment was 7.146 billion yuan, of which 5.423 billion yuan was expended R&D investment.